These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 35315251)

  • 1. Model-based meta-analysis of salbutamol pharmacokinetics and practical implications for doping control.
    Courlet P; Buclin T; Biollaz J; Mazzoni I; Rabin O; Guidi M
    CPT Pharmacometrics Syst Pharmacol; 2022 Apr; 11(4):469-481. PubMed ID: 35315251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical and pharmacological approach to adjust the salbutamol anti-doping policy in athletes.
    Pillard F; Lavit M; Cances VL; Rami J; Houin G; Didier A; Rivière D
    Respir Res; 2015 Dec; 16():155. PubMed ID: 26704899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Futility of current urine salbutamol doping control.
    Heuberger JAAC; van Dijkman SC; Cohen AF
    Br J Clin Pharmacol; 2018 Aug; 84(8):1830-1838. PubMed ID: 29722428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of exercise and dehydration on the urine concentrations of salbutamol after inhaled administration of 1600 µg salbutamol as a single dose in relation to doping analysis.
    Haase CB; Backer V; Kalsen A; Rzeppa S; Hemmersbach P; Hostrup M
    Drug Test Anal; 2016 Jul; 8(7):613-20. PubMed ID: 26044066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of salmeterol and its main metabolite α-hydroxysalmeterol after acute and chronic dry powder inhalation in exercising endurance-trained men: Implications for doping control.
    Jessen S; Becker V; Rzeppa S; Backer V; Bengtsen KH; Hullstein I; Dehnes Y; Hostrup M
    Drug Test Anal; 2021 Apr; 13(4):747-761. PubMed ID: 33210444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discrimination of prohibited oral use of salbutamol from authorized inhaled asthma treatment.
    Bergés R; Segura J; Ventura R; Fitch KD; Morton AR; Farré M; Mas M; de La Torre X
    Clin Chem; 2000 Sep; 46(9):1365-75. PubMed ID: 10973867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacokinetic profile of inhaled and oral salbutamol in elite athletes with asthma and nonasthmatic subjects.
    Elers J; Pedersen L; Henninge J; Hemmersbach P; Dalhoff K; Backer V
    Clin J Sport Med; 2012 Mar; 22(2):140-5. PubMed ID: 22388343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of ethnicity, gender, and dehydration on the urinary excretion of inhaled salbutamol with respect to doping control.
    Dickinson J; Hu J; Chester N; Loosemore M; Whyte G
    Clin J Sport Med; 2014 Nov; 24(6):482-9. PubMed ID: 24518370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinction of inhaled and oral salbutamol by urine analysis using conventional screening procedures for doping control.
    Ventura R; Segura J; Bergés R; Fitch KD; Morton AR; Berruezo S; Jiménez C
    Ther Drug Monit; 2000 Jun; 22(3):277-82. PubMed ID: 10850394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The enigma of inhaled salbutamol and sport: unresolved after 45 years.
    Fitch KD
    Drug Test Anal; 2017 Jul; 9(7):977-982. PubMed ID: 28294577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urine concentrations of repetitive doses of inhaled salbutamol.
    Elers J; Pedersen L; Henninge J; Hemmersbach P; Dalhoff K; Backer V
    Int J Sports Med; 2011 Aug; 32(8):574-9. PubMed ID: 21563035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urine concentrations of oral salbutamol in samples collected after intense exercise in endurance athletes.
    Hostrup M; Kalsen A; Auchenberg M; Rzeppa S; Hemmersbach P; Bangsbo J; Backer V
    Drug Test Anal; 2014 Jun; 6(6):528-32. PubMed ID: 24166762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doping test reveals high concentrations of salbutamol in a Swiss track and field athlete.
    Schweizer C; Saugy M; Kamber M
    Clin J Sport Med; 2004 Sep; 14(5):312-5. PubMed ID: 15377972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beta2-Agonist Doping Control and Optical Isomer Challenges.
    Jacobson GA; Fawcett JP
    Sports Med; 2016 Dec; 46(12):1787-1795. PubMed ID: 27164986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formoterol concentrations in blood and urine: the World Anti-Doping Agency 2012 regulations.
    Eibye K; Elers J; Pedersen L; Henninge J; Hemmersbach P; Dalhoff K; Backer V
    Med Sci Sports Exerc; 2013 Jan; 45(1):16-22. PubMed ID: 22843108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood and urinary concentrations of salbutamol in asthmatic subjects.
    Elers J; Pedersen L; Henninge J; Lund TK; Hemmersbach P; Dalhoff K; Backer V
    Med Sci Sports Exerc; 2010 Feb; 42(2):244-9. PubMed ID: 19927035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhaled salbutamol and doping control: effects of dose on urine concentrations.
    Sporer BC; Sheel AW; Taunton J; Rupert JL; McKenzie DC
    Clin J Sport Med; 2008 May; 18(3):282-5. PubMed ID: 18469572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preliminary data on the potential for unintentional antidoping rule violations by permitted cannabidiol (CBD) use.
    Mareck U; Fusshöller G; Geyer H; Huestis MA; Scheiff AB; Thevis M
    Drug Test Anal; 2021 Mar; 13(3):539-549. PubMed ID: 33125823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doping control from a global and national perspective.
    Fraser AD
    Ther Drug Monit; 2004 Apr; 26(2):171-4. PubMed ID: 15228160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Athlete Biological Passport: an integral element of innovative strategies in antidoping.
    Vernec AR
    Br J Sports Med; 2014 May; 48(10):817-9. PubMed ID: 24659508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.